Journal
JOURNAL OF EXTRACELLULAR VESICLES
Volume 11, Issue 5, Pages -Publisher
WILEY
DOI: 10.1002/jev2.12218
Keywords
anti-PD-1 therapy; CD73; head and heck squamous cell carcinoma; macrophage; small extracellular vesicle
Categories
Funding
- National Natural Science Foundation of China [82173217, 81672829, 81874126]
- Shanghai Committee of Science and Technology [21DZ2292000]
- SJTU Trans-med Awards Research [20210103]
Ask authors/readers for more resources
Research on tumour cell-derived small extracellular vesicles (sEVs) that regulate tumour microenvironment (TME) has provided strategies for targeted therapy of head and neck squamous cell carcinoma (HNSCC). Herein, we demonstrated that sEVs derived from HNSCC cancer cells carried CD73 (sEVs(CD73)), which promoted malignant progression and mediated immune evasion. The sEVs(CD73) phagocytosed by tumour-associated macrophages (TAMs) in the TME induced immunosuppression.
Research on tumour cell-derived small extracellular vesicles (sEVs) that regulate tumour microenvironment (TME) has provided strategies for targeted therapy of head and neck squamous cell carcinoma (HNSCC). Herein, we demonstrated that sEVs derived from HNSCC cancer cells carried CD73 (sEVs(CD73)), which promoted malignant progression and mediated immune evasion. The sEVs(CD73) phagocytosed by tumour-associated macrophages (TAMs) in the TME induced immunosuppression. Higher CD73(high) TAMs infiltration levels in the HNSCC microenvironment were correlated with poorer prognosis, while sEVs(CD73) activated the NF-kappa B pathway in TAMs, thereby inhibiting immune function by increasing cytokines secretion such as IL-6, IL-10, TNF-alpha, and TGF-beta 1. The absence of sEVs(CD73)enhanced the sensitivity of anti-PD-1 therapy through reversed immunosuppression. Moreover, circulating sEVs(CD73) increased the risk of lymph node metastasis and worse prognosis. Taken together, our study suggests that sEVs(CD73) derived from tumour cells contributes to immunosuppression and is a potential predictor of anti-PD-1 responses for immune checkpoint therapy in HNSCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available